The Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market has entered a phase of strategic expansion driven by elevated COPD prevalence and technological innovation. Industry size is witnessing steady business growth as AI-enabled imaging and remote spirometry reshape diagnostic pathways. In-house Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market analysis indicates robust market dynamics and evolving market trends across segments.

Market Size and Overview

The chronic obstructive pulmonary disease (COPD) diagnosis market is estimated to be valued at USD 2.29 billion in 2025 and is expected to reach USD 3.24 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

This in-house Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market report highlights surging business growth across imaging, spirometry, and biomarker diagnostics. Projected Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market revenue expansion reflects rising demand for AI-enabled spirometers in clinics. Current market scope and market opportunities underscore unmet needs in rural and emerging regions, while market restraints include regulatory complexities and reimbursement challenges.

Use Case Scenarios

• High-Resolution CT with AI-Assisted Quantification: Large hospital networks in the US deployed AI-driven CT platforms in late-2024, reducing diagnostic turnaround by 30% and improving early-stage detection, a key market driver in advanced care.
  • Remote Spirometry Platforms in APAC: Telehealth providers in India and China integrated cloud-based spirometers in 2025, boosting patient adherence by 45% and unlocking new market segments in rural diagnostics.
  • Point-of-Care Biomarker Panels in Oncology Centers: European oncology clinics piloted eosinophil and neutrophil assays for COPD overlap in 2024, optimizing treatment stratification and enhancing market share among precision diagnostic companies.
  
  Policy and Regulatory Impact
• 
  FDA AI-Software Guidance (2024): Issuance of draft guidelines for AI in diagnostic imaging intensified market growth strategies, streamlining approvals for novel COPD algorithms and reducing time-to-market.
  • EU In Vitro Diagnostic Regulation (IVDR) Implementation (2025): Stricter conformity assessments bolstered device quality but introduced market challenges for small-scale spirometry manufacturers, tightening market restraints.
  • Reimbursement Policy Updates in Canada (2024): Provincial health plans expanded coverage for home spirometry, fueling regional market opportunities and lifting overall industry share in North America.
  • WHO Standardization Initiative (2025): Global COPD screening protocols recommended uniform spirometric thresholds, harmonizing international standards and supporting market dynamics across emerging economies.
  
  Key Players
• 
  GlaxoSmithKline (GSK)
  • AstraZeneca
  • Boehringer Ingelheim
  • Novartis
  • Teva Pharmaceutical Industries
  • Roche Diagnostics
  • Siemens Healthineers
  • GE Healthcare
  • ResMed
  • Philips Healthcare
  • Olympus Corporation
  • Nihon Kohden
  • Drägerwerk AG
  • Contec Medical Systems
  • Becton Dickinson
  • Medtronic
  
  Strategic Activities
• 
  AstraZeneca–Siemens Healthineers Partnership (2024): Co-developed an AI backbone for CT-based COPD quantification, expected to expand combined market share in premium imaging diagnostics.
  • Boehringer Ingelheim POC Kit Approval (2025): Secured CE-mark for a point-of-care biomarker panel, unlocking new market companies in European primary-care settings and accelerating business growth.
  • Novartis APAC Expansion (2024): Established diagnostic centers in Southeast Asia, addressing underpenetrated segments and leveraging local partnerships to capture emerging market revenue.
  
  FAQs

1. 
   Who are the dominant players in the Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market?
   Leading market players include GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, Novartis, Teva Pharmaceutical, Roche Diagnostics, Siemens Healthineers and GE Healthcare, commanding significant industry share.
   
   2. What will be the size of the Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market in the coming years?
   Based on our market forecast, the market value is projected to grow from USD 2.29 Bn in 2025 to USD 3.24 Bn by 2032, driven by AI, telehealth and point-of-care diagnostic adoption.
   
   3. Which end-user industry has the largest growth opportunity?
   Hospital networks and specialty pulmonary clinics remain the primary drivers, while telehealth platforms and home-care providers represent rapidly expanding market segments by leveraging remote monitoring.
   
   4. How will market development trends evolve over the next five years?
   Trends will shift toward AI-enhanced imaging, integrated biomarker panels and cloud-connected spirometry, supporting predictive diagnostics and personalized treatment planning across segments.
   
   5. What is the nature of the competitive landscape and challenges in the Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market?
   Competition is marked by consolidation among leading diagnostic and pharmaceutical companies, with challenges including regulatory alignment, reimbursement variability and technological interoperability.
   
   6. What go-to-market strategies are commonly adopted in the Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market?
   Key strategies include strategic partnerships, regulatory approvals for AI-software and point-of-care kits, direct-sales models, and digital health integration to accelerate market penetration.
   
   ➢Get More Insights On:Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market

➢Get this Report in Japanese Language: 慢性閉塞性肺疾患（COPD）診断市場

➢Get this Report in Korean Language: 만성폐쇄성폐질환(COPD)진단시장

➢Read More Related Articles- The Emerging cGAS-STING Pathway is Poised for Growth